NuCana (NCNA) Total Current Liabilities (2016 - 2025)
NuCana's (NCNA) quarterly Total Current Liabilities came in at $6.4 million in Q4 2025, down 42.68% year-on-year from $11.1 million in Q4 2024, and down 24.66% quarter-over-quarter from $8.5 million in Q3 2025.
NuCana (NCNA) Total Current Liabilities (2016 - 2025) Analysis & Trends
NuCana has disclosed Total Current Liabilities across 10 years of filings, most recently posting $6.4 million for Q4 2025.
- Total Current Liabilities for Q4 2025 came in at $6.4 million, down 42.68% year-over-year; the trailing twelve-month figure through Dec 2025 was $6.4 million (down 42.68% YoY), and the FY2025 annual result was $6.3 million, down 42.95% from the prior year.
- Total Current Liabilities came in at $6.4 million for Q4 2025 at NuCana, down from $8.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $22.6 million in Q4 2022 to a low of $6.4 million in Q4 2025.
- The 5-year median for Total Current Liabilities is $15.8 million (2021), against an average of $15.0 million.
- Across the five-year window, Total Current Liabilities jumped 61.21% in 2021 and plunged 56.65% in 2025, its largest moves.
- NuCana's Total Current Liabilities stood at $15.8 million in 2021, then surged by 43.41% to $22.6 million in 2022, then plunged by 30.54% to $15.7 million in 2023, then dropped by 29.3% to $11.1 million in 2024, then slumped by 42.68% to $6.4 million in 2025.
- The last three Total Current Liabilities figures came in at $6.4 million (Q4 2025), $8.5 million (Q3 2025), and $11.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 13.42 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 72.86 Mn |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | 6.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.38 Mn |
| Sep 30, 2025 | 8.46 Mn |
| Jun 30, 2025 | 11.60 Mn |
| Mar 31, 2025 | 9.18 Mn |
| Dec 31, 2024 | 11.12 Mn |
| Sep 30, 2024 | 19.52 Mn |
| Jun 30, 2024 | 20.27 Mn |
| Mar 31, 2024 | 18.32 Mn |
| Dec 31, 2023 | 15.73 Mn |
| Sep 30, 2023 | 15.09 Mn |
| Jun 30, 2023 | 16.94 Mn |
| Mar 31, 2023 | 20.18 Mn |
| Dec 31, 2022 | 22.65 Mn |
| Sep 30, 2022 | 18.22 Mn |
| Jun 30, 2022 | 13.14 Mn |
| Mar 31, 2022 | 16.80 Mn |
| Dec 31, 2021 | 15.79 Mn |
| Sep 30, 2021 | 16.68 Mn |
| Jun 30, 2021 | 10.98 Mn |
| Mar 31, 2021 | 12.50 Mn |